Earnings News - Candlesense

Evaxion announces business update and second quarter 2025 financial results

COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update ...

What macro or sector trends (e.g., AI adoption in biotech, vaccine demand) could amplify or mitigate the impact of this news on EVAX shares? How might the sentiment score of 20 (presumably low) reflect broader analyst sentiment, and why might it differ from the actual news tone? Did the update include any new partnership, licensing, or acquisition activity that could affect revenue streams?

Symbol: EVAX

28 days ago

Read more globenewswire

Realbotix Reports Financial Results for Q3-2025

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt Stock Exchange: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Company”), a leading in AI-powered humanoid robots, reports its interi...

Is there any insider buying or selling activity surrounding the release of these interim results? What macro or sector trends could be influencing Realbotix's recent financial results? How does Realbotix's performance compare to its key competitors in the AI robotics sector?

Symbol: XBOT

28 days ago

REX American Resources to Report Fiscal Q2 2025 Results and Host a Conference Call and Webcast on August 27, 2025

DAYTON, Ohio--(BUSINESS WIRE)--REX American Resources Corporation (“REX” or the “Company”) (NYSE: REX), a leading ethanol production company, announced today that it will report its fiscal second q...

Are there any insider transactions or notable changes in institutional ownership around the release date that might signal market sentiment? What is the outlook for regulatory or policy changes (e.g., RFS credits, tax incentives) that could impact future earnings? Did the company announce any strategic initiatives (e.g., renewable diesel, carbon credits, new off‑take agreements) that could diversify revenue streams?

Symbol: REX

28 days ago

McGraw Hill, Inc. Reports Fiscal First Quarter 2026 Results

COLUMBUS, Ohio--(BUSINESS WIRE)--McGraw Hill, Inc. (NYSE: MH) (“McGraw Hill” or the “Company”), a leading global provider of information solutions across education from preK-12 through higher educa...

How might macroeconomic factors (e.g., inflation, interest rates, education funding) affect McGraw Hill's performance in the upcoming quarters? Are there any red flags in the financials, such as rising debt levels or deteriorating cash flow, that traders should be wary of? What impact, if any, does the reported earnings have on the company's valuation multiples (P/E, EV/EBITDA) relative to the sector?

Symbol: MH

28 days ago

IREN to Release FY25 Results on August 28, 2025

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) ("IREN") today announced that it will release its financial results for the fiscal year ended June 30, 2025, on Thursday, A...

Will the earnings call provide insights into macro‑economic or regulatory factors impacting IREN's business model? What risks or uncertainties were highlighted in the FY25 earnings release that could affect future performance? How might the FY25 results influence institutional sentiment and potential changes in ownership stakes?

Symbol: IREN

28 days ago

Read more globenewswire

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and ...

What are the key risks (clinical, regulatory, financial) that could affect the success of the Iopofosine program? What is the likely impact on analyst consensus estimates and target price after this corporate update? How might the outcome of the confirmatory trial affect the company’s long‑term strategic positioning and partnership opportunities?

Symbol: CLRB

28 days ago

Read more globenewswire

FLSmidth updates its financial guidance for 2025: Adjusted EBITA margin guidance upgraded, while revenue guidance lowered

COMPANY ANNOUNCEMENT NO. 22-2025

What is the expected impact on earnings per share and forward guidance for 2024 and beyond? How might the guidance revisions affect analyst consensus estimates and rating upgrades/downgrades? Are there any changes to capital expenditure, R&D spending, or cost‑structure initiatives that impact the margin upgrade?

Symbol: FLM

28 days ago

Read more globenewswire

reAlpha Tech Corp. Announces 1,909% Year-over-Year Revenue Growth for Quarter Ended June 30, 2025

DUBLIN, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results and...

Is there any updated guidance or earnings forecast for the next quarters or fiscal year? What potential risks (e.g., scaling challenges, technology adoption, regulatory) could temper the growth momentum? How does reAlpha’s growth outlook compare to competitors in the AI‑real‑estate space?

Symbol: AIRE

28 days ago

Read more globenewswire

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading ...

What key takeaways from the conference call could affect the stock's momentum? How might the sentiment score of 20 influence market perception and potential price movement? Are there any changes in capital structure, such as share issuances, convertible notes, or debt financing, that investors should note?

Symbol: BCLI

28 days ago

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million

What valuation multiples (e.g., EV/Sales, P/E) does the market assign after this earnings release, and are they justified by the growth outlook? Is there any anticipated dilution risk from upcoming financing rounds or convertible securities? What is the status of the product pipeline and expected timelines for product launches or commercialization?

Symbol: EVOK

28 days ago

Read more globenewswire